Swedish Orphan Biovitrum AB (publ)

OM:SOBI Stok Raporu

Piyasa değeri: SEK 99.6b

Swedish Orphan Biovitrum Yönetim

Yönetim kriter kontrolleri 3/4

Swedish Orphan Biovitrum CEO'su Guido Oelkers, May2017 tarihinde atandı, in görev süresi 7.5 yıldır. in toplam yıllık tazminatı SEK 48.88M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25.1% maaş ve 74.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.12% ine doğrudan sahiptir ve bu hisseler SEK 123.86M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 4 yıldır.

Anahtar bilgiler

Guido Oelkers

İcra Kurulu Başkanı

SEK 48.9m

Toplam tazminat

CEO maaş yüzdesi25.1%
CEO görev süresi7.5yrs
CEO sahipliği0.1%
Yönetim ortalama görev süresi5.8yrs
Yönetim Kurulu ortalama görev süresi4yrs

Son yönetim güncellemeleri

Recent updates

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Oct 27
Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19
Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08
Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27
Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Apr 24
Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 06
Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Mar 05
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 15
Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Jan 17
Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Nov 24
Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jul 07
Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Apr 02
Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

Jan 11
Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Dec 27
These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 28
Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jun 26
Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

CEO Tazminat Analizi

Guido Oelkers'un ücretlendirmesi Swedish Orphan Biovitrum'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

SEK 4b

Jun 30 2024n/an/a

SEK 2b

Mar 31 2024n/an/a

SEK 2b

Dec 31 2023SEK 49mSEK 12m

SEK 2b

Sep 30 2023n/an/a

SEK 3b

Jun 30 2023n/an/a

SEK 3b

Mar 31 2023n/an/a

SEK 3b

Dec 31 2022SEK 47mSEK 11m

SEK 3b

Sep 30 2022n/an/a

SEK 2b

Jun 30 2022n/an/a

SEK 3b

Mar 31 2022n/an/a

SEK 3b

Dec 31 2021SEK 42mSEK 10m

SEK 3b

Sep 30 2021n/an/a

SEK 3b

Jun 30 2021n/an/a

SEK 3b

Mar 31 2021n/an/a

SEK 3b

Dec 31 2020SEK 33mSEK 10m

SEK 3b

Sep 30 2020n/an/a

SEK 3b

Jun 30 2020n/an/a

SEK 3b

Mar 31 2020n/an/a

SEK 4b

Dec 31 2019SEK 33mSEK 10m

SEK 3b

Sep 30 2019n/an/a

SEK 3b

Jun 30 2019n/an/a

SEK 3b

Mar 31 2019n/an/a

SEK 3b

Dec 31 2018SEK 26mSEK 9m

SEK 2b

Sep 30 2018n/an/a

SEK 2b

Jun 30 2018n/an/a

SEK 2b

Mar 31 2018n/an/a

SEK 1b

Dec 31 2017SEK 16mSEK 5m

SEK 1b

Tazminat ve Piyasa: Guido 'nin toplam tazminatı ($USD 4.45M ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.20M ).

Tazminat ve Kazançlar: Guido 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Guido Oelkers (59 yo)

7.5yrs

Görev süresi

SEK 48,883,000

Tazminat

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Guido Oelkers
CEO & President7.5yrsSEK 48.88m0.12%
SEK 123.9m
Henrik Stenqvist
Chief Financial Officer6.3yrsVeri yok0.016%
SEK 16.3m
Torbjörn Hallberg
General Counsel & Head of Legal Affairs5.8yrsVeri yok0.0089%
SEK 8.8m
Daniel Rankin
Head of Strategy & Corporate Development2.8yrsVeri yok0.0029%
SEK 2.8m
Lena Bjurner
Head of Human Resources1.8yrsVeri yokVeri yok
Armin Reininger
Senior Scientific & Medical Advisor7.8yrsVeri yok0.0047%
SEK 4.6m
Norbert Oppitz
Head of International7.1yrsVeri yok0.012%
SEK 11.5m
Sofiane Fahmy
Head of Europe5.8yrsVeri yok0.0077%
SEK 7.7m
Duane Barnes
Head of North America3.8yrsVeri yokVeri yok
Mahmood Ladha
Head of Strategic Transformation Operationsno dataVeri yok0.0018%
SEK 1.8m
Christine Wesstrom
Head of Technical Operations2.7yrsVeri yok0.0032%
SEK 3.2m
Lydia Abad-Franch
Senior VP1.8yrsVeri yokVeri yok

5.8yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: SOBI 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Hans Wigzell
Chairman of Scientific Advisory Board23.8yrsSEK 158.00kVeri yok
Helena Saxon
Director13.6yrsSEK 828.00k0.0067%
SEK 6.6m
Anders Ullman
Director1.5yrsSEK 463.00k0.0010%
SEK 996.0k
Stephen O'Rahilly
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Ralf Pettersson
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Stefan Del Prato
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Jonathan Sanders Arch
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Annette Clancy
Independent Chairman10.5yrsSEK 770.00k0.00099%
SEK 986.0k
Staffan Schuberg
Independent Director4.5yrsSEK 827.00k0.0021%
SEK 2.1m
Filippa Stenberg
Director3.5yrsSEK 673.00k0.00017%
SEK 169.3k
Katy Mazibuko
Employee Representative Director1.8yrsVeri yok0.0013%
SEK 1.3m
Christophe Bourdon
Independent Director1.5yrsSEK 433.00kVeri yok

4.0yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SOBI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).